SCHEMBL1127888

SCHEMBL1127888

CCOC(=O)CN1CCN(C)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
TSHR P16473 1/20 0.45
HTR1A P08908 1/20 0.43
HTR2C P28335 1/20 0.43
GSK3A P49840 2/20 0.43
GSK3B P49841 2/20 0.43
MGAM O43451 1/20 0.43
GAA P10253 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
SIGMAR1 Q99720 1/20 0.42
ALOX15 P16050 1/20 0.41
ELANE P08246 1/20 0.41
HTT P42858 1/20 0.40
KDM4E B2RXH2 2/20 0.40
TRPA1 O75762 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5986631 0.98 ALDH1A1 (0.47) ALDH1A1TSHRHTR1AHTR2CGSK3A
SCHEMBL19010640 0.93 SIGMAR1 (0.53) ALDH1A1TSHRHTR1AHTR2CGSK3A
SCHEMBL3966571 0.92 MGAM (0.50) ALDH1A1TSHRHTR1AHTR2CGSK3A
SCHEMBL2373233 0.92 MGAM (0.50) ALDH1A1TSHRHTR1AHTR2CGSK3A
SCHEMBL8912811 0.92 MGAM (0.50) ALDH1A1TSHRHTR1AHTR2CGSK3A
SCHEMBL11852921 0.92
SCHEMBL18293009 0.90 PKM (0.52) ALDH1A1TSHRGSK3BGAAALOX15
SCHEMBL21465945 0.88 HTR1A (0.38) ALDH1A1TSHRHTR1AHTR2CGSK3A
SCHEMBL13296281 0.86 GSK3A (0.42) ALDH1A1TSHRGSK3AGSK3BMGAM
SCHEMBL29419289 0.86 ALDH1A1 (0.45) ALDH1A1GSK3AGSK3BMGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106459058-B Compound and composition as 7 agonist of TOLL- sample receptor 诺华股份有限公司 2019-07-05 CN claimed
CN-106459058-A COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS 诺华股份有限公司 2017-02-22 CN claimed
CN-101090883-A Substituted hydroxyethylamines ELAN PHARM INC (US) 2007-12-19 CN claimed
US-20260076982-A1 Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof COUNCIL SCIENT IND RES (IN) 2026-03-19 US disclosed
EP-4551241-A1 PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2025-05-14 EP disclosed
WO-2024009324-A1 PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2024-01-11 WO disclosed
WO-2024009324-A1 PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2024-01-11 WO disclosed
WO-2022197758-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed
US-20200055825-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. 2020-02-20 US disclosed
CN-110300586-A ANTI-INFLAMMATORY COMPOSITIONS COMPRISING IRAK AND JAK INHIBITORS 加拉帕戈斯股份有限公司 2019-10-01 CN disclosed
US-10391082-B2 Protein kinase inhibitors ORION CORPORATION (FI) 2019-08-27 US disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 US disclosed
US-20040097570-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUROSEARCH A/S 2004-05-20 US disclosed
US-20040097570-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUROSEARCH A/S 2004-05-20 US disclosed
WO-2004032824-A2 BASIC ESTERS OF FATTY ALCOHOLS AND THEIR USE AS ANTI-INFLAMMATORY OR IMMUNOMODULATORY AGENTS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2004-04-22 WO disclosed
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ELI LILLY AND COMPANY 2003-05-29 US disclosed
EP-1250340-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-10-23 EP disclosed
WO-2001046199-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-06-28 WO disclosed
WO-2000078728-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2000-12-28 WO disclosed
US-4567178-A ANTIULCER AGENTS DR. KARL THOMAE GMBH (DE) 1986-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055825-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, MDM2, ESRRA ALDH1A1 514/4885TSHR 1939/4885HTR1A 2867/4885
US-20260076982-A1 Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof CNR1, CNR2, CBR1 ALDH1A1 1408/4885TSHR 1082/4885HTR1A 174/4885
US-20040097570-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds GABRA1, GABRA2, GABRA4 ALDH1A1 977/4885TSHR 1559/4885HTR1A 1344/4885
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ABCC1, ABCB11, ABCB1 ALDH1A1 264/4885TSHR 4206/4885HTR1A 2097/4885
US-10391082-B2 Protein kinase inhibitors FGFR1, FGFR3, FGFR4 ALDH1A1 3196/4885TSHR 1845/4885HTR1A 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.